IVERIC bio Inc (ISEE) Fundamental Analysis & Valuation

NASDAQ:ISEE • US46583P1021

Current stock price

39.95 USD
+0.15 (+0.38%)
At close:
39.94 USD
-0.01 (-0.03%)
After Hours:

This ISEE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ISEE Profitability Analysis

1.1 Basic Checks

  • In the past year ISEE has reported negative net income.
  • In the past year ISEE has reported a negative cash flow from operations.
ISEE Yearly Net Income VS EBIT VS OCF VS FCFISEE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M

1.2 Ratios

  • ISEE has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ISEE Yearly ROA, ROE, ROICISEE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 100 200 300

1.3 Margins

  • ISEE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ISEE Yearly Profit, Operating, Gross MarginsISEE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ISEE Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ISEE has more shares outstanding
  • The debt/assets ratio for ISEE is higher compared to a year ago.
ISEE Yearly Shares OutstandingISEE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
ISEE Yearly Total Debt VS Total AssetsISEE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • ISEE has an Altman-Z score of 22.00. This indicates that ISEE is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 22.00, ISEE belongs to the top of the industry, outperforming 94.41% of the companies in the same industry.
  • ISEE has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
  • ISEE has a worse Debt to Equity ratio (0.20) than 69.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 22
ROIC/WACCN/A
WACCN/A
ISEE Yearly LT Debt VS Equity VS FCFISEE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 15.53 indicates that ISEE has no problem at all paying its short term obligations.
  • ISEE's Current ratio of 15.53 is amongst the best of the industry. ISEE outperforms 87.97% of its industry peers.
  • ISEE has a Quick Ratio of 15.53. This indicates that ISEE is financially healthy and has no problem in meeting its short term obligations.
  • ISEE has a better Quick ratio (15.53) than 87.97% of its industry peers.
Industry RankSector Rank
Current Ratio 15.53
Quick Ratio 15.53
ISEE Yearly Current Assets VS Current LiabilitesISEE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ISEE Growth Analysis

3.1 Past

  • ISEE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -55.75%.
EPS 1Y (TTM)-55.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ISEE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.86% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.05%
EPS Next 2Y6.29%
EPS Next 3Y25.52%
EPS Next 5Y33.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ISEE Yearly Revenue VS EstimatesISEE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
ISEE Yearly EPS VS EstimatesISEE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. ISEE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ISEE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ISEE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ISEE Price Earnings VS Forward Price EarningsISEE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ISEE Per share dataISEE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • ISEE's earnings are expected to grow with 25.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.29%
EPS Next 3Y25.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ISEE Dividend Analysis

5.1 Amount

  • No dividends for ISEE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ISEE Fundamentals: All Metrics, Ratios and Statistics

IVERIC bio Inc

NASDAQ:ISEE (7/10/2023, 8:00:03 PM)

After market: 39.94 -0.01 (-0.03%)

39.95

+0.15 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.04
Industry Growth13.66
Earnings (Last)05-10
Earnings (Next)07-24
Inst Owners0.92%
Inst Owner Change0%
Ins Owners0.05%
Ins Owner Change0%
Market Cap5.51B
Revenue(TTM)N/A
Net Income(TTM)-222.90M
Analysts52.86
Price Target39.88 (-0.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.08%
Min EPS beat(2)-22.88%
Max EPS beat(2)-11.29%
EPS beat(4)1
Avg EPS beat(4)-11.73%
Min EPS beat(4)-27.83%
Max EPS beat(4)15.07%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.38%
PT rev (3m)25.45%
EPS NQ rev (1m)-3.77%
EPS NQ rev (3m)-2.87%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-15.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.55
P/tB 11.55
EV/EBITDA N/A
EPS(TTM)-1.76
EYN/A
EPS(NY)-1.32
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS3.46
TBVpS3.46
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 456.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.53
Quick Ratio 15.53
Altman-Z 22
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-55.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.76%
EPS Next Y-21.05%
EPS Next 2Y6.29%
EPS Next 3Y25.52%
EPS Next 5Y33.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-86.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.94%
EBIT Next 3Y31.5%
EBIT Next 5Y39.62%
FCF growth 1Y-127.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.44%
OCF growth 3YN/A
OCF growth 5YN/A

IVERIC bio Inc / ISEE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IVERIC bio Inc (ISEE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ISEE.


Can you provide the valuation status for IVERIC bio Inc?

ChartMill assigns a valuation rating of 1 / 10 to IVERIC bio Inc (ISEE). This can be considered as Overvalued.


Can you provide the profitability details for IVERIC bio Inc?

IVERIC bio Inc (ISEE) has a profitability rating of 0 / 10.